Optimi Health Corp OPTH

🚨 $OPTH | PSYCHEDELICS WITH REVENUE ! Optimi Health is one of the few psychedelic names already generating sales. Psilocybin + MDMA capsules sold under Australia's Authorized Prescriber Scheme • Health Canada GMP + export licences • Psilocybin supplied for a UK Phase 2 trial $15M raised on 2026 Nasdaq uplisting • Pipeline: Phase 2 psilocybin: up to 200 MDD patients •Phase 3 MDMA: up to 100 PTSD patients •Enrolment targeted for 2027 New Chief Clinical Development Officer (Dr. Michael Blough) + Melanie Pump joins the Board. CommunicatedDisclaimer:http://stockresearchtoday.com/opth/

$OPTH on watch 👀 ✅ Already generating revenue, not just clinical-stage ✅ Health Canada GMP-licensed psilocybin + MDMA maker ✅ Supplying Australia, Canada, UK ✅ Fresh $15M Nasdaq raise ✅ US upside if rescheduling hits Communicated-Disclaimer https://stockresearchtoday.com/opth/

$OPTH THE PATH TO A MUCH BIGGER MARKET Optimi Health is making a major move from psychedelic manufacturing into its own clinical development programs. 🧬 Phase 2 Psilocybin: up to 200 patients with Major Depressive Disorder 🧬 Phase 3 MDMA: up to 100 patients with PTSD 🧬 300 patients combined across two Health Canada authorized trials 🧬 Latest 5mg psilocybin batch manufactured for both clinical + commercial use 🧬 Already commercially supplying regulated markets including Australia How could OPTH monetize this? 💰 Optimi manufactures its own drugs + owns its clinical data, creating potential for registrations, licensing and global commercial sales. With programs targeting Major Depressive Disorder + PTSD, OPTH is pursuing multibillion dollar treatment markets 💰 Analyst Coverage: On May 27, 2026, Diamond Equity Research initiated coverage with an illustrative DCF valuation of $15.00 per share Communicated Disclaimer: https://stockresearchtoday.com/opth/ Sector Peers: $CMPS $ATAI $IXHL

$OPTH — the price did not move. The story did. Optimi closed the day where it opened the week. Still ~$4.83. Still under the $5.15–$5.20 shelf. Cap $28M. Float ~4.5M. That is not a failed break. That is a coil that has not been asked yet. What changed is the book around it. Health Canada licence. cGMP plant in Princeton, B.C. 5mg psilocybin already shipping to Australia for treatment-resistant depression — prescribed and reimbursed. Phase 2 for major depression, up to 200 patients. Phase 3 MDMA for PTSD, up to 100 veterans and frontline. Melanie Pump joined the board today — 25+ years of finance and public-company work. Depression still hits about 1 in 19 adults. Most names in this group are a trial and a slide. This one already has product moving. Weekly: washed to $4.00, rising line into the shelf. Measured move if $5.20 goes is +88% toward ~$9. Lose $4.00 and the coil was just a base Simple close. Supply is live. Trials are authorized Disclaimer: https://stockresearchtoday.com/opth/

$OPTH ADDS MORE EXPERIENCE TO THE BOARD Optimi Health appointed Melanie Pump to its Board of Directors, bringing 25+ years of senior finance and leadership experience. ▫️ 25+ years in finance and corporate leadership ▫️ 20+ years working with public companies ▫️ Currently CFO of Qu Data Centres ▫️ Experience across technology, fintech and high growth companies ▫️ OPTH is advancing a Phase 2 psilocybin trial for up to 200 patients and a Phase 3 MDMA trial for up to 100 patients More financial and governance experience being added as OPTH continues building out its clinical and commercial strategy. Sector Peers: $CMPS $ATAI $GHRS

$OPTH — already shipping. The market is still wide open. Depression hits about 5.2% of adults worldwide. Roughly 1 in 19. PTSD sits on top of that. Most psychedelic names are still a slide. Optimi is not. Health Canada drug licence. cGMP plant in Princeton, B.C. 5mg psilocybin already going to Australia for treatment-resistant depression — prescribed and reimbursed. MDMA capsules in the same stack. Product is moving into regulated markets, not waiting on a press release. What is next: 🔸 Phase 2 psilocybin for major depression — up to 200 patients 🔸 Phase 3 MDMA for PTSD — up to 100 veterans and frontline workers 🔸 Melanie Pump just joined the board — 25+ years of finance and public-company work Float ~4.5M. Weekly is coiled under $5.20. A close over that shelf opens $6.65, then the old $8–$9 zone. $4.00 is the line that cannot go. Commercial supply is live. Trials are authorized. The board just got heavier. That is the setup. Disclaimer: https://stockresearchtoday.com/opth/

$OPTH — 4.5M float. Already commercial. Optimi Health is one of the few tiny-cap psychedelic plays that’s actually shipping product. Health Canada Drug Establishment Licence + GMP facility in B.C. Already producing and exporting naturally derived psilocybin and synthetic MDMA capsules. Product is moving into Australia under the TGA Authorised Prescriber scheme for treatment-resistant depression and PTSD. Not waiting on milestones — they have commercial revenue today, supply clinical programs, and are scaling formulations. Pipeline: Phase 2 psilocybin for major depressive disorder (up to 200 patients) + Phase 3 MDMA-assisted therapy for PTSD (up to 100 veterans/frontline). Cap sits at $28M. Float ~4.5M. Weekly coil is tight. Washed to $4, now testing the $5.15–$5.20 shelf. Break higher opens $6.65 then the old $8–$9 zone. Commercial manufacturing + real exports + clinical pipeline in a 4.5M float name. Asymmetric setup worth watching. Disclaimer: https://stockresearchtoday.com/opth/

🚨 $OPTH | THE CLINICAL STORY IS GETTING BIGGER 🍄 Optimi is moving beyond manufacturing and building out its clinical pipeline. New developments: • Melanie Pump just joined the Board • Dr. Michael Blough appointed Chief Clinical Development Officer • Phase 2 psilocybin trial targeting up to 200 MDD patients • Phase 3 MDMA trial targeting up to 100 PTSD patients • Both trials expected to begin enrolling in 2027 The key here: $OPTH already has commercial psychedelic supply — now it’s building the clinical data around its own products. 2027 could be a major year for the pipeline. 🔥 CommunicatedDisclaimer:http://stockresearchtoday.com/opth/